Sunitinib-induced hyperammonaemia in a patient with pancreatic neuroendocrine tumour.
What is known and objective Sunitinib can improve progression-free survival and overall survival in patients with advanced pancreatic neuroendocrine tumor ( PNET). From clinical trial, most commonly reported adverse events of sunitinib were neutropenia (12%), diarrhea (10%), asthenia (7%), erythrody...
| Publicado en: | Journal of Clinical Pharmacy & Therapeutics Vol. 38; no. 4; pp. 327 - 330 |
|---|---|
| Autores principales: | , , , , |
| Formato: | case study tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Aug2013
|
| Acceso en línea: | Ver este registro en EBSCOhost |